Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

This publication has 45 references indexed in Scilit:

• A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer
  Radiotherapy and Oncology, 2006
• Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
  European Journal Of Cancer, 2006
• Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy
  Journal of Clinical Oncology, 2006
• Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation Therapy
  Journal of Clinical Oncology, 2005
• Technological advances in radiotherapy for the treatment of localised prostate cancer
  Published by Elsevier ,2005
• Quality improvement report Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study Commentary: presenting unbiased information to patients can be difficult
  BMJ, 2002
• Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
  Statistics in Medicine, 2002
• The UCLA Prostate Cancer Index
  Medical Care, 1998
• LENT SOMA tables table of contents
  Radiotherapy and Oncology, 1995
• The MOS 36-ltem Short-Form Health Survey (SF-36)
  Medical Care, 1992